India markets closed
  • BSE SENSEX

    40,522.10
    +376.60 (+0.94%)
     
  • Nifty 50

    11,889.40
    +121.65 (+1.03%)
     
  • Dow

    27,685.38
    -650.19 (-2.29%)
     
  • Nasdaq

    11,358.94
    -189.34 (-1.64%)
     
  • BTC-INR

    986,870.19
    +17,436.19 (+1.80%)
     
  • CMC Crypto 200

    266.64
    +3.22 (+1.22%)
     
  • Hang Seng

    24,787.19
    -131.59 (-0.53%)
     
  • Nikkei

    23,485.80
    -8.54 (-0.04%)
     
  • EUR/INR

    87.1372
    -0.1859 (-0.21%)
     
  • GBP/INR

    96.0112
    -0.2109 (-0.22%)
     
  • AED/INR

    20.0320
    -0.0480 (-0.24%)
     
  • INR/JPY

    1.4182
    +0.0026 (+0.18%)
     
  • SGD/INR

    54.2100
    -0.1010 (-0.19%)
     

Pharma In Focus - Dr Reddy's, Cipla & Lupin

Pharma sector is in focus with newflows around key drugs for large cap Pharma companies. Dr. Reddy's has announced a settlement on gRevlimid (A $7.5bn annual size drug) in the US.

The launch date is post Mar-2022 (which is settled date with Teva/Natco) and there are caps defined on volume market share in each of the years (not disclosed).

Credit Suisse says for Dr.Reddy In base case they are building in its launch in FY23 and volume share equivalent to half of Teva.

In another important development in Pharma sector within six months of launch has announced a voluntary nationwide recall of gProAir (Albuterol Sulfate) in the US.

Analyst say his setback for Perrigo comes as an unexpected positive for Lupin and Cipla, Perrigo’s competitors in the US$850- 900m (normalised) US Albuterol Sulfate market.